Studies on Immunologic Overlap Among Certain Arthropod-Borne Viruses

Parks, James J.; Ganaway, James R.; Price, Winston H.

doi:10.1093/oxfordjournals.aje.a119955

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to solubilized antigen I, antigen III did not absorb a significant amount of anti-SLEneutralizing antibodies even at high antigen concentrations. DISCUSSION The previously reported antigenic relationships among group B togaviruses of the SLE-JBE-WN complex and dengue-2 viruses and the solubilized envelope protein reported here are in agreement with those described by other workers (11,15,19 as those prepared from infected mouse brain (Fig. 1, 2).…”

Section: Resultssupporting

confidence: 92%

“…This problem becomes even more complex when attempting to distinguish between different viruses within antigenically closely related subgroups. Serological studies indicate that, during group B arbovirus infections, antibodies are formed which crossreact with antigens produced by other viruses within the complex (7,11,15,17,30). Sera from animals and humans infected with viruses belonging to the dengue subgroup contain antibodies which neutralize Saint Louis encephalitis (SLE), Japanese B encephalitis (JBE), and West Nile (WN) viruses (2,3,12,14,23).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Group B Arbovirus Structural and Nonstructural Antigens III. Serological Specificity of Solubilized Intracellular Viral Proteins

Qureshi

Trent

1973

Infect Immun

View full text Add to dashboard Cite

Solubilized nonstructural antigen III from Saint Louis encephalitis (SLE)-Japanese B encephalitis (JBE)-West Nile (WN) and dengue-2 arbovirus-infected pig kidney cells was purified by employing Brij-58 solubilization, organic solvent extraction, and column chromatography. Diethylaminoethyl-cellulose column peak C eluate contained only intracellular viral envelope protein designated antigen I. Antigen I of SLE virus absorbed homologous neutralizing antibody; however, the intracellular nonstructural protein designated antigen III did not. The antigenic relationships of solubilized antigens I and III prepared from SLE, JBE, and WN virus-infected cells were determined by complement-fixation (CF) and immunodiffusion analyses. Solubilized antigen I of each virus cross-reacted broadly with both homologous and heterologous antibody at high antigen concentrations in the CF test. Antigen III of each virus reacted with only homologous antibody by both CF and immunoprecipitation. This study demonstrates that during SLE, JBE, WN, and dengue-2 infections, virus-specific proteins containing both type-specific and group-reactive determinants are synthesized. Antigen III, a nonstructural protein, is serologically virus type specific and may be useful as a type-specific diagnostic reagent. specific determinants. The soluble viral non-99:3

show abstract

Section: Resultssupporting

confidence: 92%

mentioning

confidence: 99%

Group B Arbovirus Structural and Nonstructural Antigens III. Serological Specificity of Solubilized Intracellular Viral Proteins

Qureshi

Trent

1973

Infect Immun

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15] Individual strains of CHIK are closely related antigenically, 9,16,17 and infection with one CHIK strain leads to protection against all strains. 18 Reciprocal cross-protection after infection with other alphaviruses occurs in animal models, 19,20 although it is unclear if similar cross protection occurs in humans sequentially exposed to natural infection or live alphavirus vaccines. 21 An isolate from a patient in Thailand, CHIK strain 15561, was used to develop a small lot of vaccine first passaged in green monkey kidney (GMK) cells and then formalin-inactivated before administration to 16 volunteers.…”

Section: Introductionmentioning

confidence: 99%

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Edelman¹,

Tacket²,

Wasserman³

et al. 2000

The American Journal of Tropical Medicine and Hygiene

284

229

View full text Add to dashboard Cite

Abstract. We conducted a phase II, randomized, double-blind, placebo-controlled, safety and immunogenicity study of a serially passaged, plaque-purified live chikungunya (CHIK) vaccine in 73 healthy adult volunteers. Fiftynine volunteers were immunized one time subcutaneously with the CHIK vaccine and 14 were immunized with placebo (tissue culture fluid). Vaccinees were clinically evaluated intensively for one month, and had repeated blood draws for serological assays (50% plaque-reduction neutralization test) for one year. Except for transient arthralgia in five CHIK vaccinees, the number and severity of local and systemic reactions and abnormal laboratory tests after immunization were similar in CHIK vaccinees and placebo recipients. Fifty-seven (98%) of 58 evaluable CHIK vaccinees developed CHIK neutralizing antibody by day 28, and 85% of vaccinees remained seropositive at one year after immunization. No placebo recipients seroconverted. This promising live vaccine was safe, produced well-tolerated side effects, and was highly immunogenic.

show abstract

“…Analysis of SLEV isolates also showed a high degree of concordance between the level and duration of viremia in birds (90) and mosquitoes (91) and neurovirulence for mice and monkeys. However, in one study a correlation between neurovirulence in mice and primates with several strains of WNV (92) could not be demonstrated.…”

Section: Factors Influencing Viral Neurovirulencementioning

confidence: 95%

Flaviviruses

Brinton

1989

Clinical and Molecular Aspects of Neurotropic Virus Infection

View full text Add to dashboard Cite

Studies on Immunologic Overlap Among Certain Arthropod-Borne Viruses

Cited by 9 publications

References 0 publications

Group B Arbovirus Structural and Nonstructural Antigens III. Serological Specificity of Solubilized Intracellular Viral Proteins

Group B Arbovirus Structural and Nonstructural Antigens III. Serological Specificity of Solubilized Intracellular Viral Proteins

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Flaviviruses

Contact Info

Product

Resources

About